Tracers to monitor the response to chemotherapy: in vitro screening of four radiopharmaceuticals.
de Geus-Oei
Lioe-Fee
LF
Department of Nuclear Medicine, University Medical Center, Nijmegen, The Netherlands. L.degeus-oei@nucmed.umcn.nl
van Eerd-Vismale
Julliëtte
J
Molthoff
Carla
C
Corstens
Frans
F
Oyen
Wim
W
Boerman
Otto
O
D004247:DNA / Q000096:biosynthesis; D004317:Doxorubicin / Q000627:therapeutic use; D018432:Drug Resistance, Multiple; D019008:Drug Resistance, Neoplasm; D019788:Fluorodeoxyglucose F18 / Q000493:pharmacokinetics*; D006801:Humans; D007065:Idoxuridine / Q000493:pharmacokinetics*; D007457:Iodine Radioisotopes; D008297:Male; D008781:Methyltyrosines / Q000493:pharmacokinetics*; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D009943:Organophosphorus Compounds / Q000493:pharmacokinetics*; D015609:Organotechnetium Compounds / Q000493:pharmacokinetics*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics*; D014700:Verapamil / Q000494:pharmacology
D007457:Iodine Radioisotopes; D008781:Methyltyrosines; D009943:Organophosphorus Compounds; D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18; C078700:technetium tc-99m tetrofosmin; D004317:Doxorubicin; D004247:DNA; D014700:Verapamil; D007065:Idoxuridine